Antimicrobial susceptibility of Staphylococcus aureus isolated from hospital inpatients, 2009: Report from the Australian Group on Antimicrobial Resistance
DOI:
https://doi.org/10.33321/cdi.2011.35.22Keywords:
antibiotic resistance, Staphylococcus aureus, nosocomialAbstract
In 2009, the Australian Group on Antimicrobial Resistance (AGAR) conducted a period-prevalence survey of clinical Staphylococcus aureus isolated from hospital inpatients. Thirty medical microbiology laboratories from each state and mainland territory participated. Specimens were collected more than 48 hours post-admission. Isolates were tested by Vitek2® (AST-P579 card) and by Etest for daptomycin. Nationally, the proportion of S. aureus that were MRSA was 33.6%, ranging from 27.3% in South Australia to 41.4% in New South Wales/Australian Capital Territory. Resistance to the non-β-lactam antimicrobials was common except for rifampicin, fusidic acid, daptomycin and high-level mupirocin. No resistance was detected for vancomycin, teicoplanin, quinupristin-dalfopristin or linezolid. Resistance in the methicillin susceptible S. aureus (MSSA) was rare apart from erythromycin (12%) and absent for vancomycin, teicoplanin, daptomycin, quinupristin-dalfopristin and linezolid. The proportion of methicillin resistant S. aureus (MRSA) has remained stable since the first AGAR inpatient survey in 2005 yet during the same time frame resistance to many antimicrobials, in particular tetracycline, trimethoprim-sulphamethoxazole and gentamicin, has significantly decreased. This suggests that non-multi-resistant community-associated MRSA (CA-MRSA) clones are becoming more common in the hospital setting and replacing the long-established multi-resistant clones such as ST239-III (Aus 2/3 EMRSA). Given hospital outbreaks of CA-MRSA are thought to be extremely rare it is most likely that patients colonised at admission with CA-MRSA have become infected with the colonising strain during their hospital stay. Commun Dis Intell 2011;35(3):237–243.
Downloads
References
Turnidge J, Kotsanas D, Munckhof W, Roberts S, Bennett C, Nimmo G, et al. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust 2009;191(7):368–373.
Turnidge J. Australia New Zealand cooperative on outcomes in staphylococcal sepsis. Antimicrobials 2009, Melbourne, February 2009.
Coombs GW, Van Gessel H, Pearson JC, Godsell MR, O’Brien F,G Christiansen KJ. Controlling a multicentre outbreak involving the New York/Japan methicillin resistant Staphylococcus aureus clone. Infect Control Hosp Epidemiol 2007;28(7):845–852.
Gavalda L, Masuet C, Beltran J, Garcia M, Garcia D, Sirvent J, et al. Comparative cost of selective screening to prevent transmission of methicillin-resistant Staphylococcus aureus (MRSA), compared with the attributable costs of MRSA infection. Infect Control Hosp Epidemiol 2006;27(11):1264–1266.
Lucet JC, Chevret S, Durand-Zaleski I, Chastang C, Regnier B. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicentre study. Arch Intern Med 2003;163(2):181–188.
Bassetti M, Righi E, Ansaldi F, Molinari M, Rebesco B, McDermott J, et al. Impact of limited cephalosporin use on prevalence of methicillin-resistant Staphylococcus aureus in the intensive care unit. J Chemother 2009;21(6):633–638.
Madaras-Kelly K, Remington R, Lewis P, Stevens D. Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol 2006;27(2):155–169.
Spelman D, Harrington G, Russo P, Wesselingh S. Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery. Infect Control Hosp Epidemiol 2002;23(7):402–404.
Grayson M, Jarvie L, Martin R, Johnson P, Jodoin M, McMullan C, et al. Significant reductions in methicillin-resistant Staphylococcus aureus bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. Med J Aust 2008;188(11):633–640.
McLaws ML, Pantle AC, Fitzpatrick KR, Hughes CF. More than hand hygiene is needed to affect methicillin resistant Staphylococcus aureus clinical indicator rates: clean hands save lives part IV. Med J Aust 2009;191 Suppl:S26–S31.
Nimmo G, Bell J, Collignon P. Fifteen years of surveillance by the Australian Group for Antimicrobial Resistance. Commun Dis Intell 2003;27 Suppl:S47–S54.
Coombs G, Nimmo G, Pearson J, Christiansen K, Bell J, Collignon P, et al. Prevalence of MRSA strains among Staphylococcus aureus isolated from outpatients, 2006: Report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell 2009;33(1):10–20.
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. M100-S21. CLSI, Villanova, PA, USA; 2011.
Comite de L’antibiogramme de la Societe Francaise de microbiologie. Recommendations 2010. Available from: www.sfm-microbiologie.org
Cosgrove S, Sakoulas G, Perencevich E, Schwaber M, Karchmer A, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36(1):53–59.
Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001;175:264–267.
European Centre for Disease Prevention and Control Surveillance Report: Antimicrobial resistance surveillance in Europe, 2009. Available from: www.ecdc.europa.eu
Nimmo GR, Bell JM, Mitchell D, Gosbell IB, Pearman JW, Turnidge JD. Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals 1989–1999. Microb Drug Resist 2003;9(2):155–160.
Coombs G, Pearson J, O’Brien F, Christiansen K. Molecular epidemiology of MRSA in Australian hospitals. Antimicrobials 2007, Melbourne, February 2007.
Coombs G, Pearson J, Nimmo G, Christiansen K. Staphylococcus aureus Programme 2007 (SAP 2007) Hospital Survey, MRSA Epidemiology and Typing Report. Available from: www.antimicrobial-resistance.com
O’Brien FG, Pearman JW, Gracey M, Riley TV, Grubb WB. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 1999;37(9):2858–2862.
Schlebusch S, Price GR, Hinds S, Nourse C, Schooneveldt JM, Tilse MH, et al. First outbreak of PVL-positive nonmultiresistant MRSA in a neonatal ICU in Australia: comparison of MALDI-TOF and SNP-plus-binary gene typing. Eur J Clin Microbiol Infect Dis 2010;29(10):1311–1314.
Chua K, Laurent F, Coombs G, Grayson M, Howden B. Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician’s guide to community MRSA—its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 2011;52(1):99–114.
Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, et al. Emergence of multidrug-resistant, community associated, methicillin resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann intern Med 2008;148(4):249–257.
Coombs G, Pearson J, Christiansen K, Nimmo G. Widespread dissemination of the Panton-Valentine leucocidin ST93-MRSA-IV (Qld CA-MRSA) clone in the Australian community. 20th European Congress on Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2010.
Pearson J, Coombs G, Tan H-L, Cramer S, Wilson L, Chew Y, et al. Introduction of a multi-resistant Panton-Valentine leucocidin positive community associated MRSA into Western Australia. International Symposium on Staphylococci and Staphylococcal Infections, Bath, UK, September, 2008.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2011 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
